Orthocell Limited (ASX: $OCC) has requested an immediate trading halt in accordance with ASX Listing Rule 17.1. The halt is pending an announcement regarding the receipt of regulatory approval for Striate in Canada. The company has requested that the trading halt remain in place until the earlier of making an announcement in relation to the approval or the opening of trading on Friday, 12 July 2024.
The trading halt request is in line with our commitment to transparent communication with the market. We are awaiting regulatory approval for Striate in Canada, and this halt ensures that the market is informed of any developments as soon as possible. We believe that this step is necessary to maintain market integrity and provide equal access to information for all investors.
Orthocell Limited (ASX: $OCC) has requested a trading halt pending an announcement related to the receipt of regulatory approval for Striate in Canada. The company emphasizes its dedication to transparent communication and equal access to information for all investors. The request reflects the company's commitment to keeping the market informed of significant developments. The outcome of the regulatory approval will likely have an impact on the company's future operations and market position, and the company looks forward to updating the market as soon as possible.